The prevalence and direct costs of multiple sclerosis therapy in Poland from 2008 to 2016

Andrzej Jacyna; Andrzej Śliwczyński; Jarosław Stachurski; Monika Zbylut; Justyna Gałek; Piotr Eliasz; Andrzej Łabenda; Krzysztof Gajewski; Beata Kasińska; Gabriela Majkut; Katarzyna Janaszek; Katarzyna Wiktorzak; Dariusz Dziełak; Waldemar Wierzba; Adam Kozierkiewicz; Urszula Jaworska; Mariusz Skrzypek; Małgorzata Gałązka-Sobotka; Konrad Jantarski; Melania Brzozowska; Michał Marczak; Ewa Orlewska

doi:10.5114/ms.2018.74817

eISSN: 2300-6722
ISSN: 1899-1874

Medical Studies/Studia Medyczne

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2018
vol. 34

Send email

Copy url:

abstract:

Original paper

The prevalence and direct costs of multiple sclerosis therapy in Poland from 2008 to 2016

Andrzej Jacyna

,

Andrzej Śliwczyński

,

Jarosław Stachurski

,

Monika Zbylut

,

Justyna Gałek

,

Piotr Eliasz

,

Andrzej Łabenda

,

Krzysztof Gajewski

,

Beata Kasińska

,

Gabriela Majkut

,

Katarzyna Janaszek

,

Katarzyna Wiktorzak

,

Dariusz Dziełak

,

Waldemar Wierzba

,

Adam Kozierkiewicz

,

Urszula Jaworska

,

Mariusz Skrzypek

,

Małgorzata Gałązka-Sobotka

,

Konrad Jantarski

,

Melania Brzozowska

,

Michał Marczak

,

Ewa Orlewska

Medical Studies/Studia Medyczne 2018; 34 (1): 9-14

DOI: https://doi.org/10.5114/ms.2018.74817

Online publish date: 2018/03/30

View full text Get citation

PlumX metrics:

Aim of the research
Analysis of prevalence of multiple sclerosis (MS) and direct healthcare costs of patients with MS in Poland between 2008 and 2016.

Material and methods
Retrospective analysis of data on healthcare services related to the treatment of patients with MS covered by National Health Fund (NHF) in 2008-2016. The Number of patients with MS, utilization of resources, and direct medical cost were analyzed for each year in 9-year time horizon. Costs were calculated from public payer perspective and reported in EuroPPP (adjusted for purchasing power parity).

Results
According to data from the NHF, the prevalence of MS in Poland was 103,06 and 113,06 per 100,000 population in 2008 and 2016, respectively. The annual growth rate of spending’s on MS (+14%) was higher than the growth rate of patients (+1.3%). In the years 2008-2016, the average expenditure per patient increased from 2,800 to 6,900 EuroPPP. The largest group of patients was treated the out-patient setting (36% specialized, 29.3% primary care); however, 84% of funds were spent on hospital care. The main drivers for hospital costs were therapeutic/drug programs, which increased from 59 million in 2008 to 233 million EuroPPP in 2016. Currently, 25% of the MS population has access to publicly funded drug programs.

Conclusions
The situation of patients with MS in Poland is systematically improving. Over the past 9 years, both the public payer’s expenditure on treatment of MS patients and the number of patients participating in drug programs funded by NHF have tripled.

keywords:

The prevalence and direct costs of multiple sclerosis therapy in Poland from 2008 to 2016

multiple sclerosis, epidemiology, morbidity, regional variations